ECE2018 Guided Posters Thyroid Cancer - Diagnostics & Treatments (12 abstracts)
Related recurrence factors in a Spanish cohort of differentiated thyroid carcinoma. Cadit-CAM Study
Iván Quiroga 1 , Julia Sastre 2 , Manuel Delgado 3 , Silvia Aznar 4 , Visitación Álvarez 5 , Belvis Torres 6 , Javier González 7 , Cristina Lamas 4 , Mary Gaby Llaro 1 , Florentino del Val 6 , Dulce Calderón 7 & Jose Lop 2
1Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain; 2Complejo Hospitalario de Toledo, Toledo, Spain; 3Hospital General Universitario de Ciudad Real, Ciudad Real, Spain; 4Complejo Hospitalario Universitario de Albacete, Albacete, Spain; 5Hospital Universitario de Guadalajara, Guadalajara, Spain; 6Hospital General la Mancha Centro, Alcazar de San Juan, Spain; 7Hospital Virgen de la Luz, Cuenca, Spain.
Background and objective: Incidence of differentiated thyroid cancer (DTC) is increasing but not its mortality. Knowing recurrence factors is essential to plan its treatment. Recurrence related factors in our area were reviewed and compared with ATA risk stratification system.
Patients and Methods: The Cadit-CAM study was designed to evaluate characteristics of patients diagnosed of DTC in Castilla La Mancha, a region in the central part of Spain, during 15 years (from 2001 to 2015). The cohort in Cadit-CAM study included 1434 patients from seven regional hospitals. The variables analyzed were: sex, age, size, histopathologic subtype, multifocality, involved lymph nodes, lymphadenectomy, extrathyroidal extension, metastases at diagnosis (MTS), intentionally total thyroidectomy (ITT), anti-thyroglobulin antibodies with rising titers (TG-Ab). Treatments and evolution of patients who recurred were also evaluated.
Results: 324 patients recurred (23%), being 82% ATA high risk (71 patients), 33% ATA intermediate risk (160) and 9% ATA low risk (93). Factors independently related to recurrence were MTS with OR 46.7 (95% CI 13–165); TG-Ab 4.86 (2.4–9.9); positive lymph nodes 4.38 (2.7–6.9), multifocality 2.2 (1.59–3.05), extrathyroidal extension 2.09 (1.4–3.1), size >3 cm 1.83 (1.23–2.72); male 1.64 (1.15–2.32). Those not statistically related to recurrence were ITT 1.33 (0.82–2.1); age 0.99 (0.98–1); lymphadenectomy 0.8 (0.5–1.28) and histology 0.7 (0.34–1.41). Recurrence treatments were: Iodine-131 (56%); surgery (31%), both (23%), kinase inhibitors (5%), observation (8%), and palliative surveillance, radiotherapy, cementation, and chemotherapy (<1%), For patients with recurrence the outcome at the end of the follow up was: 26% alive without evidence of disease, 24% alive with structural disease, 27% indeterminate or biochemically incomplete response and 10% died for DTC
Conclusion: 23% of the patients with DTC recurred. Recurrence poor prognosis factors were MTS, TG-Ab, involved lymph nodes, multifocality, extrathyroidal extention, tumor size and male sex. ATA Risk stratification predicts recurrence, however two third of these patients were in ATA intermediate and low risk groups.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more